Prevalence and Clinical Outcomes of Sarcopenia in Patients with Esophageal, Gastric or Colorectal Cancers Receiving Preoperative Neoadjuvant Therapy: A Meta-analysis

Overview

Journal Asia Pac J Oncol Nurs

Publisher Elsevier

Date 2024 Apr 15

PMID 38618524

Authors

Lin Luo

Yidan Fan

Yanan Wang

Zhen Wang

Jian Zhou

Affiliations

Soon will be listed here.

Abstract

Objective: To investigate the prevalence of sarcopenia and its impact on clinical outcomes in patients with esophageal, gastric, or colorectal cancer (EC, GC, and CRC) receiving neoadjuvant therapy through Meta-analysis.

Methods: We searched the PubMed, Embase databases, and Cochrane Library for the prevalence of sarcopenia and its impact on clinical outcomes in EC, GC, or CRC patients treated with neoadjuvant therapy (NAT) from inception to November 2022. The primary endpoints were the prevalence of sarcopenia and overall survival in patients with EC, GC, or CRC treated with NAT. Secondary outcomes included recurrence-free survival, total postoperative complications, grade 3-4 chemotherapy toxicity, and 30-day mortality after surgery.

Results: Thirty-one retrospective studies with 3651 subjects were included. In a fixed-effects model, the prevalence of muscle loss was higher in patients with EC, GC, or CRC at 50% (95% CI = 42% to 58%). The results of the multivariate analysis showed that preoperative patients with sarcopenia had a 1.91 times shorter overall survival (95% CI = 1.61-2.27) and a 1.77 times shorter recurrence-free survival time (95% CI = 1.33-2.35) than patients without sarcopenia, and that patients with sarcopenia had a higher risk of total postoperative complications than patients without sarcopenia OR = 1.27 (95% CI = 1.03-1.57). However, the two groups had no statistical difference in grade 3-4 chemotherapy toxicity ( = 0.84) or 30-d postoperative mortality ( = 0.88).

Conclusions: The prevalence of sarcopenia in patients with EC, GC, or CRC during NAT is high, and it is associated with poorer clinical outcomes. Clinicians should closely monitor the changes in patients' body composition and guide patients to carry out a reasonable diet and appropriate exercise to improve their poor prognosis and quality of life.

Systematic Review Registration: CRD42023387817.

Citing Articles

Artificial Intelligence-Driven Volumetric Analysis of Muscle Mass as a Predictor of Tumor Response to Neoadjuvant Chemoradiotherapy in Patients with Rectal Cancer.

Kim M, Lee S, Son I, Kang J, Noh G, Oh B J Clin Med. 2024; 13(23).

PMID: 39685473 PMC: 11642062. DOI: 10.3390/jcm13237018.

Textbook oncological outcome of locally advanced gastric cancer patients with preoperative sarcopenia: a multicenter clinical study.

Zhong Q, Zheng Z, Wu D, Shang-Guan Z, Liu Z, Jiang Y Surg Endosc. 2024; 39(1):356-367.

PMID: 39548007 DOI: 10.1007/s00464-024-11397-3.

Prevalence of Sarcopenia Determined by Computed Tomography in Pancreatic Cancer: A Systematic Review and Meta-Analysis of Observational Studies.

Lainez Ramos-Bossini A, Gamez Martinez A, Luengo Gomez D, Valverde-Lopez F, Melguizo C, Prados J Cancers (Basel). 2024; 16(19).

PMID: 39409977 PMC: 11475355. DOI: 10.3390/cancers16193356.

References

den Boer R, Jones K, Ash S, van Boxel G, Gillies R, ODonnell T . Impact on postoperative complications of changes in skeletal muscle mass during neoadjuvant chemotherapy for gastro-oesophageal cancer. BJS Open. 2020; 4(5):847-854. PMC: 7528528. DOI: 10.1002/bjs5.50331. View

Yang M, Shen Y, Tan L, Li W . Prognostic Value of Sarcopenia in Lung Cancer: A Systematic Review and Meta-analysis. Chest. 2019; 156(1):101-111. DOI: 10.1016/j.chest.2019.04.115. View

Tantai X, Liu Y, Yeo Y, Praktiknjo M, Mauro E, Hamaguchi Y . Effect of sarcopenia on survival in patients with cirrhosis: A meta-analysis. J Hepatol. 2021; 76(3):588-599. DOI: 10.1016/j.jhep.2021.11.006. View

Dupont J, Dedeyne L, Dalle S, Koppo K, Gielen E . The role of omega-3 in the prevention and treatment of sarcopenia. Aging Clin Exp Res. 2019; 31(6):825-836. PMC: 6583677. DOI: 10.1007/s40520-019-01146-1. View

Gallois C, Bourillon C, Auclin E, Artru P, Lievre A, Lecomte T . Skeletal muscle loss during chemotherapy and its association with survival and systemic treatment toxicity in metastatic colorectal cancer: An AGEO prospective multicenter study. Clin Res Hepatol Gastroenterol. 2021; 45(6):101603. DOI: 10.1016/j.clinre.2020.101603. View

Nishimura E, Matsuda S, Kawakubo H, Okui J, Takemura R, Takeuchi M . The impact of thoracic duct resection on the long-term body composition of patients who underwent esophagectomy for esophageal cancer and survived without recurrence. Dis Esophagus. 2023; 36(9). PMC: 10473448. DOI: 10.1093/dote/doad002. View

Simonsen C, Heer P, Bjerre E, Suetta C, Hojman P, Pedersen B . Sarcopenia and Postoperative Complication Risk in Gastrointestinal Surgical Oncology: A Meta-analysis. Ann Surg. 2018; 268(1):58-69. DOI: 10.1097/SLA.0000000000002679. View

Jarvinen T, Ilonen I, Kauppi J, Salo J, Rasanen J . Loss of skeletal muscle mass during neoadjuvant treatments correlates with worse prognosis in esophageal cancer: a retrospective cohort study. World J Surg Oncol. 2018; 16(1):27. PMC: 5809976. DOI: 10.1186/s12957-018-1327-4. View

Ozawa Y, Nakano T, Taniyama Y, Sakurai T, Onodera Y, Kamiya K . Evaluation of the impact of psoas muscle index, a parameter of sarcopenia, in patients with esophageal squamous cell carcinoma receiving neoadjuvant therapy. Esophagus. 2019; 16(4):345-351. DOI: 10.1007/s10388-019-00670-3. View

10.

Reisinger K, Bosmans J, Uittenbogaart M, Alsoumali A, Poeze M, Sosef M . Loss of Skeletal Muscle Mass During Neoadjuvant Chemoradiotherapy Predicts Postoperative Mortality in Esophageal Cancer Surgery. Ann Surg Oncol. 2015; 22(13):4445-52. PMC: 4644199. DOI: 10.1245/s10434-015-4558-4. View

11.

Mayanagi S, Tsubosa Y, Omae K, Niihara M, Uchida T, Tsushima T . Negative Impact of Skeletal Muscle Wasting After Neoadjuvant Chemotherapy Followed by Surgery on Survival for Patients with Thoracic Esophageal Cancer. Ann Surg Oncol. 2017; 24(12):3741-3747. PMC: 5658455. DOI: 10.1245/s10434-017-6020-2. View

12.

Steffl M, Bohannon R, Sontakova L, Tufano J, Shiells K, Holmerova I . Relationship between sarcopenia and physical activity in older people: a systematic review and meta-analysis. Clin Interv Aging. 2017; 12:835-845. PMC: 5441519. DOI: 10.2147/CIA.S132940. View

13.

Chen L, Woo J, Assantachai P, Auyeung T, Chou M, Iijima K . Asian Working Group for Sarcopenia: 2019 Consensus Update on Sarcopenia Diagnosis and Treatment. J Am Med Dir Assoc. 2020; 21(3):300-307.e2. DOI: 10.1016/j.jamda.2019.12.012. View

14.

Mirkin K, Luke F, Gangi A, Pimiento J, Jeong D, Hollenbeak C . Sarcopenia related to neoadjuvant chemotherapy and perioperative outcomes in resected gastric cancer: a multi-institutional analysis. J Gastrointest Oncol. 2017; 8(3):589-595. PMC: 5506267. DOI: 10.21037/jgo.2017.03.02. View

15.

Miyata H, Sugimura K, Motoori M, Fujiwara Y, Omori T, Yanagimoto Y . Clinical Assessment of Sarcopenia and Changes in Body Composition During Neoadjuvant Chemotherapy for Esophageal Cancer. Anticancer Res. 2017; 37(6):3053-3059. DOI: 10.21873/anticanres.11660. View

16.

Liu J, Motoyama S, Sato Y, Wakita A, Kawakita Y, Saito H . Decreased Skeletal Muscle Mass After Neoadjuvant Therapy Correlates with Poor Prognosis in Patients with Esophageal Cancer. Anticancer Res. 2016; 36(12):6677-6685. DOI: 10.21873/anticanres.11278. View

17.

Anandavadivelan P, Malberg K, Vikstrom K, Nielsen S, Holdar U, Johar A . Home-based physical activity after treatment for esophageal cancer-A randomized controlled trial. Cancer Med. 2023; 12(3):3477-3487. PMC: 9939163. DOI: 10.1002/cam4.5131. View

18.

Ceglia L, Niramitmahapanya S, Da Silva Morais M, Rivas D, Harris S, Bischoff-Ferrari H . A randomized study on the effect of vitamin D₃ supplementation on skeletal muscle morphology and vitamin D receptor concentration in older women. J Clin Endocrinol Metab. 2013; 98(12):E1927-35. PMC: 3849671. DOI: 10.1210/jc.2013-2820. View

19.

Awad S, Tan B, Cui H, Bhalla A, Fearon K, Parsons S . Marked changes in body composition following neoadjuvant chemotherapy for oesophagogastric cancer. Clin Nutr. 2011; 31(1):74-7. DOI: 10.1016/j.clnu.2011.08.008. View

20.

Xia L, Zhao R, Wan Q, Wu Y, Zhou Y, Wang Y . Sarcopenia and adverse health-related outcomes: An umbrella review of meta-analyses of observational studies. Cancer Med. 2020; 9(21):7964-7978. PMC: 7643685. DOI: 10.1002/cam4.3428. View